Skip to Content

Combigan Approval History

  • FDA approved: Yes (First approved October 30th, 2007)
  • Brand name: Combigan
  • Generic name: brimonidine tartrate and timolol maleate
  • Dosage form: Ophthalmic Solution
  • Company: Allergan plc
  • Treatment for: Intraocular Hypertension, Glaucoma

Combigan (brimonidine tartrate and timolol maleate) is an alpha adrenergic receptor agonist and beta adrenergic receptor inhibitor combination ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Development History and FDA Approval Process for Combigan

Oct 31, 2007Approval Allergan, Inc. Receives FDA Approval for Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%
Dec 21, 2006Allergan Announces FDA Issues Approvable Letter for Combigan 0.2%/0.5%

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.